TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01638702

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow up of complications
Description: Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up of complications
Description: Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
Study: NCT02110420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 10mg will be administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 30mg will be administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 60mg will be administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 120mg will be administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 240mg will be administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 10mg will be administered daily for 14 days
Study: NCT02880878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Surgical Hematoma Evacuation
Description: Early Minimally Invasive Parafascicular Surgery (MIPS)
Study: NCT02042950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m\^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
Study: NCT02157285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor Counseling
Description: Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
Study: NCT02222545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721
Study: NCT01468194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing procedure 1
Description: inhalation during one step, exhalation during the next step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing procedure 2
Description: inhalation and exhalation during one step
Study: NCT05225844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
Study: NCT04001218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of hypertonic saline
Description: Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Isotonic saline
Description: Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
Study: NCT01496963

Intervention type: OTHER
Intervention: Physician standard-of-care according to ESC/ERS Guidelines
Description: Physician standard-of-care

Intervention type: OTHER
Intervention: Physician standard-of-care according to ESC/ERS Guidelines
Description: Physician standard-of-care
Study: NCT02389725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: disposable elastic tourniquet
Description: Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood pressure cuff
Description: Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
Study: NCT01496963

Intervention type: OTHER
Intervention: Physician standard-of-care according to ESC/ERS Guidelines
Description: Physician standard-of-care
Study: NCT06350370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural orifice specimen extraction
Description: We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
Study: NCT02110420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 30mg will be administered daily for 14 days
Study: NCT01102257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 EFA Supplement
Description: The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
Study: NCT02110420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 60mg will be administered daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 120mg will be administered daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 240mg will be administered daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered once daily for up to 14 days depending on the Part of the study
Study: NCT03804229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide soft capsule
Description: 700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft capsule
Description: 700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
Study: NCT02110420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 480mg will be administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 720mg will be administered as a single oral dose
Study: NCT03836183

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pleuropulmonary ultrasound with clinical examination
Description: Pleuropulmonary ultrasound associate with a clinical examination
Study: NCT00860535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Biomarker evaluation
Description: Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a \~3.5 month period.~Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day \[qd\]), dasatinib (recommended dose 70 mg twice a day \[bid\]), or nilotinib (recommended dose 400 mg bid).~Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I.
Study: NCT01551264

Intervention type: DEVICE
Group type: OTHER
Intervention: Foot Abduction Brace (FAB)
Description: After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.

Intervention type: DEVICE
Group type: OTHER
Intervention: Foot Abduction Brace (FAB)
Description: After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
Study: NCT00943956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Study: NCT00223626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate
Description: the maximum topiramate test dose is 200 mg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: the maximum topiramate test dose is 200 mg/d.
Study: NCT00545961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: mixture, 0.28125 ml/kg twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin clavulanate acid
Description: mixture 0.28125 ml / kg twice a day for 7 days
Study: NCT02701010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured training and leaflet
Description: The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured training
Description: The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: The patients who were given only educational leaflet were included in this group.
Study: NCT02110420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 480mg will be administered daily for 14 days
Study: NCT04222205

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous breathing trial (SBT) crossover sequence 1
Description: SBTs with T-piece breathing for one hour during odd-numbered months and SBTs with inspiratory pressure augmentation for one hour during even-numbered months.
Study: NCT00943956

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study: NCT04222205

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT) crossover sequence 2
Description: SBTs with inspiratory pressure augmentation for one hour during odd-numbered months and SBTs with T-piece breathing for one hour during even-numbered months.
Study: NCT00788957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion
Study: NCT02701010

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
Study: NCT01870362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic (Inersan)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00788957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Ganitumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Ganitumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab for intravenous infusion
Study: NCT00992680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX Anastomotic Coupler System (ACS)
Description: The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
Study: NCT03931681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-179
Description: OKI-179 single agent
Study: NCT01819246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aphersis Treatment Arm

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Study: NCT01653015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Vaccine
Description: Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
Study: NCT02719990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
Study: NCT03295513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Veneered zirconia
Description: he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia
Description: Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
Study: NCT03527355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT
Description: Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
Study: NCT01653015

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Attenuated Influenza Vaccine
Description: Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
Study: NCT03527355

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi-DT
Description: Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluQuadri™
Description: Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FluQuadri™
Description: Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride isotonic solution
Description: Manufacture: Euro-Med Inc. Dose: 0.5 mL
Study: NCT04376554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin-clavulanate
Description: amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days
Study: NCT00421434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
Study: NCT00788957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT02879617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
Study: NCT01055275

Intervention type: DEVICE
Intervention: Implantation with a Cook Iliac Branch Graft
Description: Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
Study: NCT04616638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training for Empowerment (RT-POWER)
Description: The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A traditional RT intervention
Description: The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
Study: NCT02849145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 7,5 ml of patient peripherical blood will be collected at each blood sample.
Study: NCT02288845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant
Study: NCT02706860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT02578667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gorbly Compression Device
Description: The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant
Study: NCT00788957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg almorexant
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg almorexant
Study: NCT00719381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
Study: NCT03231839

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caloric restriction
Description: After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no red meat
Description: After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increased fiber intake
Description: After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
Study: NCT03231254

Intervention type: DEVICE
Intervention: Remotely Controlled Mandibular Positioner (RCMP)
Description: RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.

Intervention type: DEVICE
Intervention: Remotely Controlled Mandibular Positioner (RCMP)
Description: RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
Study: NCT03105609

Intervention type: DEVICE
Intervention: Hyperspectral imaging
Description: Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.